PhoenixBio Co., Ltd.

Tokyo Stock Exchange 6190.T

PhoenixBio Co., Ltd. Capital Expenditure for the year ending March 31, 2024: USD -256.17 K

PhoenixBio Co., Ltd. Capital Expenditure is USD -256.17 K for the year ending March 31, 2024, a -175.18% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • PhoenixBio Co., Ltd. Capital Expenditure for the year ending March 31, 2023 was USD -93.09 K, a -67.36% change year over year.
  • PhoenixBio Co., Ltd. Capital Expenditure for the year ending March 31, 2022 was USD -55.62 K, a 96.62% change year over year.
  • PhoenixBio Co., Ltd. Capital Expenditure for the year ending March 31, 2021 was USD -1.65 M, a -490.14% change year over year.
  • PhoenixBio Co., Ltd. Capital Expenditure for the year ending March 31, 2020 was USD -278.97 K.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
SV Wall Street
Tokyo Stock Exchange: 6190.T

PhoenixBio Co., Ltd.

CEO Takashi Shimada
IPO Date March 18, 2016
Location Japan
Headquarters 3-4-1 Kagamiyama
Employees 70
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.

StockViz Staff

February 8, 2025

Any question? Send us an email